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Interleukin-6 (IL-6) and Notch signaling are important regulators of breast cancer stem cells (CSCs), which drive the
malignant phenotype through self-renewal, differentiation, and development of therapeutic resistance. We
investigated the role of integrin-linked kinase (ILK) in regulating IL-6–driven Notch1 activation and the ability to
target breast CSCs through ILK inhibition. Ectopic expression/short hairpin RNA-mediated knockdown of ILK,
pharmacological inhibition of ILK with the small molecule T315, Western blot analysis, immunofluorescence, and
luciferase reporter assays were used to evaluate the regulation of IL-6–driven Notch1 activation by ILK in IL-6–
producing triple-negative breast cancer cell lines (MDA-MB-231, SUM-159) and in MCF-7 and MCF-7IL-6 cells. The
effects of ILK on γ-secretase complex assembly and cellular localization were determined by immunofluores-
cence, Western blots of membrane fractions, and immunoprecipitation. In vivo effects of T315-induced ILK
inhibition on CSCs in SUM-159 xenograft models were assessed by mammosphere assays, flow cytometry, and
tumorigenicity assays. Results show that the genetic knockdown or pharmacological inhibition of ILK suppressed
Notch1 activation and the abundance of the γ-secretase components presenilin-1, nicastrin, and presenilin
enhancer 2 at the posttranscriptional level via inhibition of caveolin-1-dependent membrane assembly of the γ-
secretase complex. Accordingly, knockdown of ILK inhibited breast CSC-like properties in vitro and the breast CSC(to H.-L.H.). Conflicts of interest: All authors have no conflicts of interest to disclose.
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498 Function of Integrin-Linked Kinase Hsu et al. Neoplasia Vol. 17, No. 6, 2015subpopulation in vivo in xenograft tumor models. Based on these findings, we propose a novel function of ILK in
regulating γ-secretase–mediated Notch1 activation, which suggests the targeting of ILK as a therapeutic approach
to suppress IL-6–induced breast CSCs.
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Cancer stem cells (CSCs) or tumor-initiating cells represent a small
subpopulation of tumor cells harboring the capacity of self-renewal
and multilineage differentiation, thereby providing a reservoir of cells
that maintain the heterogeneous population of the tumor [1].
Moreover, preclinical and clinical data have suggested that CSCs are
responsible for tumor recurrence after chemotherapy or radiation
therapy as these cells can survive and repopulate the tumor with
drug-resistant phenotype [2]. Thus, targeting the tumor cell
subpopulation that exhibits stem cell–like properties will help
improve outcomes for patients with cancer [3].
Accumulating evidence suggests an intricate relationship between
interleukin-6 (IL-6) and Notch signaling in regulating breast CSCs
[3]. For example, IL-6 has been reported to promote breast cancer
bone metastasis through Notch1 [4] and to induce mammosphere
formation in breast cancer cells through Notch3 [5]. Signaling
through Notch involves four receptor isoforms (Notch1-4) and at
least five ligands (Jagged1/2, Delta-like 1/3/4) in mammals.
Activation of Notch through ligand binding stimulates γ-secretase,
an enzyme complex consisting of the catalytic component pre-
senilin-1 (PS1) and the three cofactors nicastrin (NCT), the
presenilin enhancer 2 (PEN-2), and the anterior pharynx-defective
protein 1, leading to the cleavage of Notch and release of the Notch
intracellular domain (NICD) into the cytoplasm. Subsequently,
NotchNICD enters the nucleus to act as a transcriptional co-activator
for the expression of Notch target genes, including those encoding
hairy and enhancer of split-1 (HES1), hairy/enhancer-of-split related
with YRPW motif protein 1 (HEY1), ATP-binding cassette
subfamily G member 2 (ABCG2), and c-myc. The oncogenic role
of this Notch activation was demonstrated by the promotion of breast
tumorigenesis in vivo by Notch1NICD or Notch3NICD in transgenic
animals [6,7]. Moreover, clinical samples show an association
between elevated expression of Notch ligands/receptors and poor
outcome in patients with breast cancer, especially those of triple
negative breast cancer [8,9]. Therefore, therapeutic targeting of the
Notch pathway might represent a relevant strategy for improving
outcomes in breast cancer [10].
Integrin-linked kinase (ILK) is an integrin-interacting protein with
serine/threonine kinase activity that phosphorylates Akt, glycogen
synthase kinase 3β (GSK3β), integrin β1/β3, α chain nascent
polypeptide-associated complex, myosin phosphatase targeting sub-
unit 1, and myosin light chain 2 in a cell line– and/or context-specific
manner [11]. Substantial evidence has demonstrated the involvement
of ILK in regulating processes associated with aggressive phenotype,
such as cell proliferation, survival, migration, and invasion, and its
expression correlates with tumor grade and poor patient outcome in
multiple cancer types [12]. The majority of ILK is localized to the
membrane as a scaffold protein where it forms complexes with various
partners, including pinch, parvin, paxillin, phosphoinositide-dependentkinase 1, Akt, rictor, Src, integrin β1/β3, and F-actin. ILK is responsive
to extracellular signals transduced through integrin or receptor tyrosine
kinases in the membrane to regulate the actin cytoskeleton, stabilize
microtubules, and transfer intracellular signaling cascades [13].
The functional link between ILK and Notch was first reported in
leukemic cells, in which ILK acts as a critical prosurvival factor [14]. It
was found that pharmacological inhibition of ILK by the
small-molecule inhibitor QLT0267 blocked Notch activation
through the suppression of Akt/GSK3β signaling. In addition, ILK
was shown to activate Notch through a Wnt-dependent mechanism
in the course of chicken embryo somitogenesis [15]. Conversely, ILK
has been reported to suppress Notch activation in NIH3T3 mouse
embryonic fibroblast and human embryonic kidney–293 cells by
direct binding and phosphorylation of Notch1NICD, leading to
Fbw7-mediated degradation [16]. These conflicting results might
arise from a cell type– and/or cellular context–specific role of ILK in
regulating Notch activation, which warrants investigation.
Previously, we demonstrated that ILK is involved in regulating the
IL-6–nuclear factor (NF)-κB signaling in breast cancer by acting as a
downstream effector induced by IL-6 (unpublished data). In this study,
we obtained evidence that ILK plays a crucial role in IL-6–driven
Notch1 activation by regulating the integrity of the γ-secretase complex
in caveolae, a type of lipid raft that forms distinct cup-shaped
invaginations in the plasma membrane, in a caveolin-1–dependent
manner. shRNA-mediated knockdown or pharmacological inhibition
of ILK suppressed the expression of Notch1NICD and downstream
targets in IL-6–producing MDA-MB-231 and SUM-159 cells, as well
as MCF-7IL-6 cells (an IL-6–overexpressing stable clone of MCF-7)
[17]. Conversely, overexpression of ILK in MCF-7 cells upregulated
Notch signaling. Our data suggest that IL-6–induced Notch activation
by ILK was attributable to its ability to regulate the assembly/stability of
the γ-secretase complex in caveolae. It is noteworthy that ILK
inhibition, through knockdown or pharmacological inhibition,
diminished the expression of PS1, NCT, and PEN-2 at the
posttranscriptional level and, consequently, the membrane assembly
of the γ-secretase complex. Furthermore, the ability of ILK to regulate
Notch1 signaling was manifested by the suppressive effect of short
hairpin (sh)RNA-mediated ILK knockdown on breast CSC-like
properties in vitro and the breast CSC subpopulation in vivo in
xenograft tumor models. On the basis of these findings, we propose a
novel mechanism by which ILK regulates Notch activation by
facilitating γ-secretase complex assembly in caveolae, which might
foster new therapeutic strategies for targeting IL-6–induced breast CSC.
Materials and Methods
Detailed descriptions and additional information on agents,
antibodies, cell culture, lentivirus preparation, immunoblot analysis,
reporter assays, and other methods, as indicated below, are provided
in the Supplementary Methods.
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Cells were transfected with various plasmids or small interfering
(si)RNAs using an Amaxa Nucleofection system (Amaxa Biosystems,
Gaithersburg,MD) or Lipofectamine 2000 (Life Technologies, Carlsbad,
CA) according to the manufacturers' instructions. Detailed information
on plasmid constructs are provided in the Supplementary Methods.
Mammosphere Formation Assays
Cancer cells (500 single cells in 1 ml medium per well) were plated
onto ultralow attachment 24-well plates (Corning Inc, Union City,
CA) and maintained in MammoCult Human Medium (Stemcell
Technologies, Vancouver, Canada). Cells were treated with test agent
or DMSO for 7 days, and the number of primary mammospheres
with diameters greater than 50 μm was counted at ×40 magnification
using a microscope fitted with a ruler. All experiments were
performed at least in triplicate.
RNA Isolation and Real-Time Quantitative Polymerase
Chain Reaction
Total RNA isolation, reverse transcription, and real-time quanti-
tative polymerase chain reaction were performed using standard
procedures, as described in the Supplementary Methods. All samples
including the control without a template were assayed in triplicate.
The relative number of target transcripts was normalized to the
number of human 18S transcripts found in the same sample. The
relative quantification of target gene expression was performed with
the comparative cycle threshold (CT) method.
Detergent Solubilization of γ-Secretase Complexes and Blue
Native Polyacrylamide Gel Electrophoresis
Cell membrane fractions were solubilized under native conditions
using 0.5% n-dodecyl β-D-maltoside on ice for 10 minutes. An equal
amount of protein from each sample was loaded per lane and
separated by electrophoresis on a 4% to 12% gradient Blue Native
Gel (Jule, Inc, Milford, CT) according to a procedure described by
the NativePAGE Novex Bis-Tris Gel System (Life Technologies), in
which NativeMark Unstained Protein Standard (Life Technologies)
was used as proteinmarkers. After separation, proteins were treated with
0.1% sodium dodecyl sulfate (SDS), transferred to polyvinylidene
fluoride membranes by using NuPAGE Transfer Buffer (Life
Technologies), and probed with specific antibodies.
Lipid Raft Isolation and Dot Blot Analysis
Lipid raft proteins were isolated using the FOCUS Signal Protein
Isolation kit (G Biosciences, St Louis, MO) according to the
manufacturer’s instruction, the details of which are provided in the
Supplementary Methods. To determine lipid raft isolation efficiency,
1 μl of serially diluted cell lysate from fractions with equivalent protein
content were dot-blotted on nitrocellulose membrane (GE Healthcare
Amersham). After drying, themembrane stripwas blockedwith 5%milk
in TBS buffer and then incubated with HRP-conjugated cholera toxin
(200 ng/ml; Life Technologies) in Tris-buffered saline with Tween-20
(TBST) buffer to detect the lipid raft marker, ganglioside GM1, which
was visualized by chemiluminescence (Supplementary Figure S1).
Immunofluorescence Analysis
Immunofluorescence was performed on cells seeded onto round
cover glasses in 24-well culture plates. To assess γ-secretase activity,
MDA-MB-231 cells were transfected with GFP-C99 for 24 hours
and then treated with 2 μM T315, 10 μM N-[N-(3,5-difluorophe-nacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), or DMSO
control. Cells were then fixed with 3.7% formaldehyde in
phosphate-buffered saline (PBS) buffer for 10 minutes at room
temperature and then permeabilized with PBS containing 0.5%
Triton X-100 for 5 minutes at room temperature. For experiments to
detect endogenous Notch1NICD or to examine localization of
endogenous caveolin-1, γ-secretase, and lipid raft, after treatments,
cells were fixed, permeabilized, blocked in 1% BSA in PBS buffer,
and then incubated with primary antibodies (1:200 dilution) to
Notch1V1754, PS1, and caveolin-1 followed by Alexa Fluor 488– or
Alexa Fluor 555–conjugated secondary antibodies (1:200 dilution),
each for 2 hours in PBS at room temperature. Lipid rafts were labeled by
incubating with Alexa Fluor 647–conjugated cholera toxin (100 ng/ml)
(Life Technologies) at the same time as secondary antibody
incubation. Nuclear staining and image acquisition are described
in the Supplementary Methods.
Caveolin-1 Co-Immunoprecipitation
Immunoprecipitation of caveolin-1 was conducted by following
a published procedure with slight modifications [18]. n-Octyl
D-glucopyranoside (OCTG) was used as the sole detergent in light of
its ability to solubilize caveolin-1 and caveolin-1–associated proteins
[19]. Briefly, cells were lysed in iced OCTG buffer (50 mM Tris, pH
7.5, 150 mM NaCl, 0.05% SDS, 0.5% Triton X-100, and 60 mM
OCTG), supplemented with protease inhibitor cocktail (Sigma) and
phosphatase inhibitors (10 mM NaF, 2 mM NaVO4, and 60 mM
β-glycerophosphate), for 45 minutes, and centrifuged at 12,000 rpm at
4°C for 10 minutes. Aliquots containing equal amounts of total protein
were incubated with anti–caveolin-1 or rabbit IgG negative control
antibodies at 4°C for 2 hours, followed by protein A/G sepharose beads
(Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C for overnight. The
immunoprecipitates were washed three times with OCTG buffer and
resuspended in SDS sample buffer. Caveolin-1–interacting proteins
were examined by immunoblot analysis.
ALDEFLUOR Assays
The ALDEFLUOR kit (StemCell Technologies) was used to
isolate cell populations with high aldehyde dehydrogenase enzymatic
activity as described in the manufacturer’s instructions, the details of
which are provided in the Supplementary Methods. Using a
FACSCalibur flow cytometer, ALDEFLUOR fluorescence was
excited at 488 nm, and fluorescence emission was detected using a
standard fluorescein isothiocyanate filter. The gating region of the
ALDHbr population was established on the basis of negative controls.
Animal Studies
Additional details covering mouse strain, husbandry, regulatory
approval, and methods are provided in Supplementary Methods.
To validate the importance of ILK for tumor initiation in vivo,
MDA-MB-231 cells stably expressing ILK shRNA were injected (5 ×
104 cells/0.1 ml) into the left inguinal mammary fat pad of female
nonobese diabetic/severe combined immunodeficiency (NOD/SCID)
mice. The same number of control shRNA-transfected MDA-MB-231
cells was injected into the contralateral mammary fat pad. Tumors were
measured with calipers, and the volumes were calculated weekly.
The ability of ILK inhibition by T315 to target breast CSCs in vivo
was evaluated in an established SUM-159 xenograft tumor
model [20]. Tumors were established by injection of SUM-159
cells (2 × 106 cells/0.1 ml) into the mammary fat pads of female
500 Function of Integrin-Linked Kinase Hsu et al. Neoplasia Vol. 17, No. 6, 2015NOD/SCIDmice. When tumors reached a volume of 50 to 70 mm3,
mice were randomized to two groups (n = 4-5) that received T315
(50 mg/kg) or vehicle twice daily by oral gavage for 11 days. At the end
of drug treatment, the mice were humanely killed, and tumors were
harvested and dissociated for evaluation of the CSC subpopulation by
ALDEFLUOR assay and mammosphere formation as described above
and by tumorigenicity after reimplantation into secondary, tumor-naive
NOD/SCID mice in which the emergence of tumors was monitored
twice weekly by palpation for up to 49 days post-injection.
Statistical Analysis
Statistical differences between group means for the mammosphere
formation assays, reporter assays, ALDEFLOUR assays, and
SUM-159 tumor growth experiments were determined using
unpaired t tests. For the MDA-MB-231 tumor growth experiment,
paired t tests were used. All tests were two-sided. Differences were
considered significant at P b .05.Results
Evidence that ILK Regulates Notch1 Activation
Pursuant to our finding that ILK is a downstream effector of IL-6
(unpublished), we examined the potential role of ILK as a mechanistic
link in IL-6–induced Notch1 activation by using a stable clone of the
IL-6–overexpressing MCF-7IL-6 cells that overexpress ILK shRNA
under Tet-on control (MCF-7IL-6/TRE-shILK). As shown, in the
absence of doxycycline, MCF-7IL-6/TRE-shILK cells, relative to MCF-7
parental cells, exhibited substantially higher expression of ILK andFigure 1. ILK regulated Notch activation. The effects of doxycycline
TRE-shILK cells on (A) the expression/activation status of ILK and the IL
and (B) mammosphere formation. Data are presented as means ± SD
expression of ILK in MCF-7 cells and (D) shRNA-mediated knockdo
activation status of ILK, Akt, and Notch1. (E and F) Immunoblot analys
Notch1 among four different breast cancer cell lines, and (F) the e
activation status of Notch1 and Akt in MCF-7IL-6 cells.phosphorylation of Akt, accompanied by a greater Notch1 activation,
as manifested by Notch1NICD accumulation (Figure 1A), and
increased mammosphere formation in anchorage-independent,
serum-free culture conditions (Figure 1B), a surrogate measure of
CSC expansion [21]. Doxycycline-induced ILK knockdown led to
reduced Akt phosphorylation and Notch1NICD expression
(Figure 1A) and reduced mammosphere-forming ability
(Figure 1B). Furthermore, ectopic expression of ILK mimicked the
effect of IL-6 overexpression on Notch1 activation in MCF-7 cells
(Figure 1C), suggesting the intermediary role of ILK in this IL-6–
induced cellular response. It is noteworthy that these changes in
Notch1NICD abundance were not accompanied by parallel changes in
endogenous Notch1 expression, indicating that these effects were
mediated through the regulation of Notch1 cleavage. Similarly,
shRNA-mediated knockdown of ILK in two IL-6–producing triple
negative breast cancer cell lines, MDA-MB-231 and SUM-159,
which express higher levels of ILK and Notch1NICD relative to the
IL-6–deficient MCF-7 and MDA-MB-468 cells (Figure 1E), also
resulted in the suppression of Notch1 activation (Figure 1D),
indicating that this is not a cell line–specific phenomenon.
Our data revealed that in MCF-7IL-6, MDA-MB-231, and
SUM-159 cells, ILK acts as a downstream effector of IL-6 to
facilitate Akt phosphorylation. As Akt has been shown to activate
Notch1 gene expression through NF-κB in melanoma [22], we
examined the plausible link between Akt and IL-6–driven Notch1
activation, which, however, was refuted by lack of suppressive effect
of the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 on
Notch1NICD accumulation in MCF-7IL-6 cells (Figure 1F)(Dox)–inducible shRNA-mediated knockdown of ILK in MCF-7IL-6/
-6 downstream signaling markers Akt and Notch1 by Western blot
(n= 3). (C and D) Immunoblot analysis of the effects of (C) ectopic
wn of ILK in MDA-MB-231 and SUM-159 cells on the expression/
is of (E) the differential expression/activation status of ILK, Akt, and
ffect of the PI3K inhibitor, LY294002 (20 μM), on the expression/
Figure 2. The ILK inhibitor, T315, suppressed Notch activation. (A) Immunoblot analysis of the dose-dependent effects of T315 on the
expression/activation status of Notch1 in MDA-MB-231 and SUM-159 cells. (B) Immunocytochemical analysis of the effect of T315 versus
DMSO control on the nuclear localization of Notch1NICD (using an antibody specific for the Notch1V1744 cleavage epitope) in
MDA-MB-231 cells (original magnification, ×40; scale bar, 10 μm). DAPI, 4',6-diamidino-2-phenylindole. (C) Dose-dependent suppressive
effects of T315 on Notch activation in MDA-MB-231 and SUM-159 cells expressing a luciferase reporter containing a Notch activation–
responsive transcriptional response element. Data are presented asmeans± SD (n=3). (D) Dose-dependent suppressive effects of T315
on protein expression of biomarkers associated with CSC signaling pathways mediated by Notch (HES1, c-Myc, Nestin, ABCG2), Wnt
(β-catenin), and hedgehog (Bmi1) and with epithelial-mesenchymal transition (ZEB1, Twist, and Y box-binding protein 1) in MDA-MB-231
and SUM-159 cells.
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Notch1 Activation
We further interrogated the role of ILK in mediating IL-6–driven
Notch1 activation by using the small-molecule inhibitor T315 as a
proof-of-concept compound, which inhibited the kinase activity of
immunoprecipitated ILK with inhibitory concentration 50 (IC50) of
0.6 μM [23] and suppressed the viability of breast cancer cells with
high potency (IC50: MCF-7, 2.7 μM; MCF-7
IL-6, 3.5 μM;
MDA-MB-231, 1.8 μM; SUM-159, 1.5 μM). Reminiscent of effects
observed with ILK shRNA, T315 dose-dependently suppressed the
expression level of Notch1NICD, without affecting the full-length
Notch1, in MDA-MB-231 and SUM-159 cells (Figure 2A). This
finding was confirmed by the clearance ofNotch1NICD immunostaining
from the nuclei of T315-treatedMDA-MB-231 cells (Figure 2B), as well
as the dose-dependent suppressive effect of T315 on Notch reporter
activity (Figure 2C) and the expression of various Notch downstream
targets (Figure 2D), including HES1 [24], c-Myc [25], Nestin [26], and
ABCG2 [27], in both MDA-MB-231 and SUM-159 cells. It is
noteworthy that T315-mediated down-regulation of these Notch targets
was accompanied by parallel decreases in the expression of CSC-
associated epithelial-mesenchymal transition regulators, including zinc
finger E-box binding homeobox 1 (ZEB1) [28], Twist [29], and Ybox-binding protein 1 [30], which were also reported to be downstream
effectors of ILK [13,31] (Figure 2D).Moreover, T315 was equipotent in
downregulating other CSC-associated markers, including the Wnt
signaling effector β-catenin and the hedgehog signaling effector Bmi1
(Figure 2D). Together, these findings suggest the ability of T315 to
suppress the breast CSC subpopulation by targeting Notch1 and other
CSC-associated pathways in IL-6–producing MDA-MB-231 and
SUM-159 cells.
ILK Regulates the Assembly of Functional γ-Secretase Complex
Mechanistically, Notch activation requires γ-secretase–mediated
cleavage of Notch to release Notch1NICD into the nucleus to facilitate
transcriptional regulation of target gene expression [32]. Thus, we
hypothesize that the effect of ILK on Notch activation was associated
with its ability to regulate γ-secretase–facilitated Notch1 cleavage. To
examine this mechanistic link, ILK was overexpressed in MCF-7 cells
to elicit Notch activation, which, as expected, increased the expression
of Notch1NICD and its targets, including HES1, c-Myc, Nestin, and
ABCG2 (Figure 3A). Treatment with the γ-secretase inhibitor,
DAPT, blocked this ILK-induced Notch activation, as evidenced by
the reduced expression of the aforementioned Notch targets to basal
levels (Figure 3A).
Figure 3. ILK is important for formation of functional γ-secretase complexes. (A) Immunoblot analysis of the effect of the γ-secretase
inhibitor, DAPT (10 μM), on the expression of Notch1NICD and Notch downstream targets in MCF-7 cells that ectopically express ILK. Ctl,
pCMV control. (B) Left: effects of T315 (2 μM) and DAPT (10 μM; 12- and/or 24-hour treatment) on the processing of GFP-C99 to GFP–
amyloid precursor protein intracellular domain in MDA-MB-231 cells by immunoblot analysis. Right: Immunocytochemical analysis of the
cellular distribution of the GFP fluorescence in GFP-C99-expressing MDA-MB-231 cells treated with T315 (2 μM) or DAPT (10 μM) (original
magnification, ×60; scale bar, 10 μm). (C) Use of SDS-PAGE (upper) and Blue Native PAGE (lower), followed by immunoblot analysis, to
analyze the suppressive effect of shRNA-mediated knockdown of ILK on native γ-secretase protein assemblies in the membranes of
MDA-MB-231 and SUM-159 cells. (D) Use of SDS-PAGE (left) and Blue Native PAGE (right) to assess the dose-dependent effect of T315
on γ-secretase complex formation in MCF-7IL-6 cells.
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enzyme activity was verified by the suppressive effect of T315 vis-à-vis
DAPT on the processing of GFP-tagged C-terminal fragment of
amyloid precursor protein (GFP-C99), a substrate for γ-secretase[33], to form the corresponding soluble intracellular domain (GFP–
amyloid precursor protein intracellular domain; Figure 3B, left
panel). However, in contrast to DAPT, T315 also blocked the
formation of GFP-C83, which has been reported to be generated
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accumulated when γ-secretase activity was inhibited [33]. This
finding suggests that T315 might also concomitantly block
α-secretase activity. Moreover, confocal images of MDA-MB-231
cells transiently expressing GFP-C99 revealed that, under basal
conditions, the GFP fluorescence is homogeneously distributed in the
cytoplasm and nucleus, indicating γ-secretase–mediated cleavage of
membrane-bound GFP-C99 (DMSO; Figure 3B, right panel). In
contrast, exposure of these cells to T315 or DAPT blocked the
γ-secretase–mediated cleavage, resulting in the majority of GFP
fluorescence remaining as membrane-associated punctate structures.
Moreover, we established a stable clone of MDA-MB-231 cells
that overexpress ILK shRNA under Tet-on control (MDA-MB-
231TRE-ILK shRNA). The effect of doxycycline-induced knockdown
of ILK on GFP-C99 cleavage paralleled that observed in
T315-treated MDA-MB-231 cells (Supplementary Figure S2).
Active γ-secretase is a multiprotein complex composed of PS1,
NCT, PEN-2, and anterior pharynx-defective protein 1. The
full-length PS1 is endoproteolytically processed into two fragments,
the N-terminal fragment and the C-terminal fragment [35], of which
PS1CTF is essential to γ-secretase activity [36]. Evidence indicates
that these γ-secretase components require proper serial assembly steps
or would undergo rapid degradation [36]. To shed light onto how
ILK inhibition by T315 inhibited γ-secretase enzyme activity, we
used Blue Native polyacrylamide gel electrophoresis (PAGE) to assess
the effect of shRNA-mediated knockdown of ILK on γ-secretase
protein assemblies in MDA-MB-231 and SUM-159 cells by
following an established procedure [37]. Immunoblot analysis with
antibodies specific for individual components of the complex,
including PS1CTF, NCT, and PEN-2 (Figure 3C, lower panel),
indicated that silencing of ILK in either cell line resulted in the
disappearance of the γ-secretase complex as a result of decreased
expression of γ-secretase components (Figure 3C, upper panel). A
similar disruption of the γ-secretase complex was also observed in
T315-treated MCF-7IL-6 cells. In line with the reported effect of IL-6
on Notch activation [4,5], stable IL-6 overexpression in the
MCF-7IL-6 cells increased expression of γ-secretase components
(Figure 3D, left panel), leading to higher abundance of γ-secretase
complexes than in the parental MCF-7 cells, as demonstrated by Blue
Native PAGE (Figure 3D, right panel). Reminiscent of the results
observed in ILK-silenced MDA-MB-231 and SUM-159 cells, T315
blocked this IL-6–induced increase in γ-secretase complex assembly
in a dose-dependent manner. Considering the nature of γ-secretase
activity on Notch cleavage, we also assessed the effect of T315 on the
activation of different Notch isoforms in MDA-MB-231 cells
(Supplementary Figure S3). Indeed, T315 suppressed the formation
of the NICDs of Notch1, Notch2, and Notch3 but not Notch4,
which is known to be more resistant to the γ-secretase inhibitor
DAPT. [38] Together, the above findings suggest a putative role of
ILK in mediating the effect of IL-6 on Notch1 activation through
γ-secretase complex assembly.
ILK Regulates the Localization of the γ-Secretase Complex
at Caveolae
It is noteworthy that ILK knockdown in MDA-MB-231 cells or
stable IL-6 expression in MCF-7 cells did not alter the mRNA levels
of the γ-secretase components PS1, NCT, and PEN-2 (Supplemen-
tary Figure S4), suggesting that the regulation was mediated at the
posttranscriptional level. Indeed, the results described above showedthat ILK could support γ-secretase complex assembly by regulating
expression of γ-secretase component proteins. We hypothesized that
ILK could also regulate γ-secretase by affecting its localization to lipid
rafts, of which the rationale is two-fold. First, it has been reported that
the activation of γ-secretase is associated with its translocation to lipid
rafts [39,40]. Second, ILK was reported to form complexes with
caveolin-1 [18], which is essential to the formation of caveolae. This
complex formation with ILK was reported to facilitate the correct
positioning of caveolin-1 close to the cytoplasmic membrane [41].
Pursuant to this hypothesis, we examined the effect of ILK
knockdown on the membrane localization of γ-secretase. In
MDA-MB-231TRE-shILK cells, doxycycline-induced ILK knockdown
facilitated gradual down-regulation, starting at 24 hours, of the
expression of ILK and the γ-secretase components PS1, NCT, and
PEN-2 (Figure 4A). Accordingly, we examined the effect of
doxycycline-induced ILK knockdown on the cellular distribution of
PS1, the catalytic core of γ-secretase, in MDA-MB-231TRE-shILK and
MCF-7IL-6/TRE-shILK cells at 24 hours of doxycycline treatment.
Immunocytochemical analysis indicated that, in the absence of
doxycycline, the IL-6–producing MDA-MB-231TRE-shILK and
MCF-7IL-6/TRE-shILK cells exhibited enriched association of PS1
with caveolae relative to the IL-6–deficient MCF-7 cells, as shown by
the co-localization of PS1 staining with that of the caveolae/lipid raft
markers GM1 ganglioside, which was detected by Alexa Fluor 647–
conjugated cholera toxin B staining, and caveolin-1 (Figure 4, B and
C). However, this association of PS1 with caveolae was blocked by
doxycycline-induced ILK knockdown or T315, providing evidence in
support of our hypothesis.
ILK Regulates the Assembly/Stability of the γ-Secretase
Complex through Caveolin-1
Pursuant to these findings, we examined the effect of ILK
knockdown on the association of PS1CTF and NCT with lipid raft
membrane fractions in MCF-7IL-6/TRE-shILK cells (Figure 5A). In line
with the above immunocytochemical data, MCF-7IL-6/TRE-shILK cells,
in the absence of doxycycline, showed substantially higher levels of
caveolin-1, phospho-PS1CTF, and NCT in the lipid raft fraction than
MCF-7 cells, and knockdown of ILK was accompanied by parallel
decreases in the lipid raft association of these three proteins.
Consistent with the reported mobility shift of PS1CTF after
phosphorylation [42], phospho-PS1CTF was enriched in lipid rafts,
which is crucial to γ-secretase activity [43]. It is interesting to note
that lipid raft–associated caveolin-1 exhibited a higher molecular mass
than that of the non-lipid raft counterpart. As caveolin-1 is known to
be palmitoylated in the course of transporting cholesterol to caveolae
[44], this discrepancy might be attributable to this posttranslational
modification of caveolin-1 in the lipid raft fraction. On the basis of
this finding, we hypothesized that ILK might regulate the assembly of
the γ-secretase complex in lipid raft microdomains by virtue of its
reported regulatory role on caveolin-1. We obtained two lines of
evidence in MCF-7IL-6/TRE-shILK cells to support this premise. First,
co-immunoprecipitation experiments indicated the physical interac-
tion of phospho-PS1CTF and NCT with caveolin-1, which could be
reduced by doxycycline-induced ILK knockdown (at 24 hours) or
T315 treatment (Figure 5B). Second, knockdown of caveolin-1 with
two different siRNAs decreased the localization of PS1CTF and NCT
to the lipid raft fraction (Figure 5C, right panel), which resulted in
decreased γ-secretase activity, as manifested by reduced Notch1NICD
formation detected in cell lysates (Figure 5C, left panel). Together,
Figure 4. ILK regulates the localization of the γ-secretase complex at caveolae/lipid rafts. (A) Time-dependent effect of doxycycline (Dox)–
inducible shRNA-mediated knockdown of ILK on the abundance of γ-secretase component proteins (PS1CTF, NCT, and PEN-2) in
MDA-MB-231TRE-shILK cells. (B and C) Immunocytochemical analyses of the effects of Dox-induced knockdown of ILK for 24 hours on the
localization of PS1 to caveolae in (B) MDA-MB-231TRE-shILK cells and (C) MCF-7IL-6/TRE-shILK cells. The effects of T315 (2 μM) were also
evaluated in MCF-7IL-6/TRE-shILK cells. Caveolae were identified by co-labeling with caveolin-1 antibody and Alexa Fluor 647–conjugated
cholera toxin B (CTx) staining for lipid rafts. MCF-7 cells were used as a negative control. The rectangles in the phase/DAPI images indicate
the areas magnified in the zoom images, in which the phase/DAPI images and the merged images were merged and magnified. The
dotted lines indicate the edges of cell membranes. Scale bar, 10 μm.
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mediated through caveolin-1–dependent localization of the γ-secretase
complex to caveolae/lipid rafts.
ILK Is Involved in Regulating Breast CSCs In Vivo
IL-6 has been reported to facilitate breast CSC expansion through
the inflammatory feedback loop [45]. From a mechanistic perspec-
tive, the ability of ILK to stimulate Notch signaling throughγ-secretase activation might provide a molecular basis to account for
the unique ability of IL-6 to facilitate the conversion of non–stem
cancer cells to CSCs [45]. To verify this hypothesis, we assessed the
effect of ILK inhibition on mammosphere formation in anchorage-
independent, serum-free culture conditions, which represents a
surrogate measure of CSC expansion [21,46]. Stable clones of ILK
shRNA-expressing MDA-MB-231 and SUM-159 cells exhibited a
diminished ability to form mammospheres relative to the respective
Figure 5. ILK regulates the assembly/stability of the γ-secretase complex at caveolae. (A) The distribution and relative expression of ILK,
caveolin-1 (Cav-1), phospho-PS1CTF, PS1CTF, NCT, Notch1, integrin β3 (lipid raft–associated protein), and GAPDH (glyceraldehyde
3-phosphate dehydrogenase; non–lipid raft associated protein) in the lipid raft and non–lipid raft fractions inMCF-7 versusMCF-7IL-6/TRE-shILK
cells with and without doxycycline (Dox) treatment (24 hours). (B) Co-immunoprecipitation analysis of complex formation of caveolin-1 with
the γ-secretase components PS1CTF and NCT in MCF-7IL-6/TRE-shILK cells, and the suppressive effect of Dox-induced shRNA-mediated ILK
knockdown and T315 (2 μM) for 24 hours on this complex formation. (C) Suppressive effects of siRNA-mediated knockdown of caveolin-1
(Cav) on Notch1 activation (left) and lipid raft localization of PS1CTF and NCT (right) in MCF-7IL-6 cells.
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capability to form tumors from low cell numbers, we assessed the
effect of ILK knockdown on tumor initiating ability by injecting
50,000 stable ILK shRNA-expressing (MDA-MB-231ILK KD) or
control (MDA-MB-231Ctl KD) MDA-MB-231 cells into the
mammary fat pads of NOD/SCID mice. Although ILK-knocked-
down cells were able to form tumors in all injected mice, they grew at
a relative slower rate (Figure 6B).
Pursuant to the above findings, we used T315 as a proof-of-concept to
demonstrate the therapeutic relevance of targeting ILK to suppress the
breast CSC population in vivo by using a previously reported SUM-159
xenograft tumor model [20]. NOD/SCID mice bearing established
SUM-159 tumors (50-70 mm3) in mammary fat pads were treated with
T315 at 50mg/kg twice daily by oral gavage orwith vehicle. T315 reduced
tumor volume by 70% by the end of the 11-day treatment (Figure 6C).
The twice-daily oral administration of T315was well tolerated, as no overt
signs of toxicity and no loss of body weight were observed.
Reminiscent of the in vitro effects of T315 (Figure 2A), this
suppression of tumor growth in T315-treated mice was associated with
a 75% reduction in the abundance of intratumoral Notch1NICD,
relative to vehicle control (Pb .001; Figure 6D).Moreover, the ability ofT315 to suppress the CSC subpopulation in these xenograft tumors was
corroborated by two lines of evidence. First, ALDEFLUOR analysis of
aldehyde dehydrogenase activity, a breast CSC marker [47], and
mammosphere formation assays of dispersed tumor cells revealed that
T315 treatment led to approximately 60% reduction in the ALDHbr
population and mammosphere formation (Figure 6E) relative to that in
control mice. Second, we assessed the ability of dispersed tumor cells
isolated from T315- and vehicle-treated SUM-159 tumor-bearing mice
to initiate tumors on secondary reimplantation of 1000 cells in
mammary fat pads of naive NOD/SCID mice. As shown in Table 1,
only one of eight mice serially transplanted with re-isolated
T315-treated SUM-159 tumor cells developed a palpable tumor,
while five of eight in the control group formed tumors by 7 weeks
post-injection, confirming the in vivo suppressive effect of T315 on the
breast CSC population within tumors. Together, these findings suggest
the translational potential of targeting ILK to suppress breast CSCs,
which warrants further investigations.
Discussion
ILK has been reported to play a dichotomous role, either as an
activator or as a suppressor, in regulating Notch in different biologic
Figure 6. ILK is required for breast CSCs in vivo. (A) Suppressive effect of stable shRNA-mediated ILK knockdown on mammosphere
formation by MDA-MB-231 and SUM-159 cells. Data are presented as means ± SD (n = 3). (B) Suppressive effect of stable
shRNA-mediated ILK knockdown on MDA-MB-231 xenograft tumor growth in nude mice. Control and ILK knocked-down MDA-MB-231
cells (5 × 104 cells/mouse) were injected into the right and left inguinal mammary fat pads, respectively, of NOD/SCID mice, and tumor
volumes were calculated from serial caliper measurements. (Inset) Images of control (Ctl) and ILK knocked-down (KD) xenograft tumors
before and after dissection from a representative tumor-bearing mouse. Data are presented as means ± SEM (n = 6). (C) Suppressive
effect of oral T315 (50 mg/kg, twice daily) on SUM-159 xenograft tumor growth in NOD/SCID mice after 7 and 11 days of treatment. (D)
Western blot analysis of the effect of T315 on the abundance of Notch1NICD in SUM-159 xenograft tumors. Left: Immunoblot of five
representative tumors from each group. Right: Corresponding densitometric analysis expressed as relative expression of Notch1NICD,
after normalization to β-actin (means ± SD; *P b .001 compared with vehicle). (E) Top: T315 decreased the percentage of the ALDHbr
subpopulation in SUM-159 xenograft tumors, as determined by ALDEFLOUR assays using tumor cells isolated from T315-treated versus
vehicle-treated SUM-159 tumor-bearing mice. Data are presented as means ± SD (n = 5). Bottom: T315 diminished the
mammosphere-forming ability of tumor cells isolated from T315-treated versus vehicle-treated SUM-159 tumor-bearing mice. Data are
presented as means ± SD (n = 4). (F) Diagram depicting the role of ILK in regulating IL-6–induced Notch1 activation and CSC expansion
through γ-secretase assembly at the caveolae.
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Table 1. Tumorigenicity of SUM-159 Tumors Cells Harvested from T315- and Vehicle-Treated
Mice and Reimplanted into Mammary Fat Pads of Naive Mice (1000 Cells per Mouse).
Treatment of
Primary Tumor-Bearing
Mice (per os, Twice Daily)
Tumor Incidence in Secondary
Mice (n = 8) at 3 and 7 Weeks
after Tumor Cell Reimplantation
3 Weeks 7 Weeks
Vehicle 3/8 5/8
T315 1/8 1/8
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GSK3β and Wnt signaling pathways in leukemic cells [14] and
during somitogenesis in chicken embryo [15], respectively. Con-
versely, ILK was demonstrated to directly bind and phosphorylate
NotchNICD, thereby promoting Fbw7-facilitated proteasomal degra-
dation of NotchNICD, in NIH3T3 and HEK 293 cells [16]. This
discrepancy underscores the complexity of the role of ILK in
regulating Notch signaling in different malignant versus nonmalig-
nant cell systems.
Within this context, we propose a new mechanism by which ILK
facilitates IL-6–driven Notch1 activation by regulating the assembly/
stability of the γ-secretase complex (Figure 6F). Specifically, ILK is
responsible for the localization of γ-secretase to caveolae, leading to
Notch1 cleavage to release Notch1NICD. Accordingly, our data
showed that the siRNA-mediated knockdown or pharmacological
inhibition of ILK led to the disassembly/instability of γ-secretase,
leading to reduced NotchNICD release from Notch1 and other Notch
isoforms. As ILK has been reported to be present in caveolae-enriched
membranes and contains a putative caveolin-binding domain [18], we
hypothesized that the effect of ILK on γ-secretase assembly/stability
might be mediated through caveolin-1, although the exact mecha-
nism remains unclear. This premise was supported by the formation
of PS1CTF–caveolin-1 complexes and the ability of ILK knockdown
or T315 to reduce this physical interaction between PS1 and
caveolin-1 and, consequently, γ-secretase activity. Although ILK
mediates Ser473-Akt phosphorylation in response to IL-6 stimulation
in breast cancer cells, our data suggest that this IL-6–driven Notch1
activation was independent of Akt signaling, as the PI3K inhibitor
LY294002 exhibited no appreciable suppressive effect on Notch1NICD
expression in MCF-7IL-6 cells (Figure 1F). Moreover, our data indicate
that ILK was not involved in IL-6–stimulated up-regulation of Notch1
expression in breast cancer cells, despite a recent report that Akt
activated Notch1 gene expression through NF-κB in melanoma [22],
The mechanism by which ILK regulates the assembly/stability of
the γ-secretase complex in caveolae is currently under investigation. It
is plausible that ILK might phosphorylate γ-secretase components,
thereby facilitating their interaction with caveolin-1. Alternatively,
ILK might act as a scaffold protein to mediate the localization of
γ-secretase to caveolae. It has been reported that ILK regulates
caveolar trafficking by controlling microtubule dynamics and that loss
of ILK function impairs the transport of caveolin-1–containing
vesicles along microtubules to the plasma membrane to form new
caveolae. The functional role of ILK in this regard is to recruit
IQGAP1 and stabilize microtubules locally following insertion of
caveolae into the plasma membrane [48]. Although T315 was
developed as an ILK kinase inhibitor that competes with ATP
binding, the ability of T315 to block this localization raises apossibility that T315 binding might induce conformational changes
that prohibit the interaction of ILK with its binding partner.
Although active γ-secretase is known to localize to lipid rafts, our
findings suggest that the interaction between γ-secretase and caveolin-1
is essential for directing the localization of γ-secretase to caveolae,
specialized membrane microdomains that can regulate multiple signaling
pathways, including those mediated by c-Met, the type I insulin-like
growth factor receptor, matrix metalloproteases, estrogen receptor,
and IL-6. As clinical evidence has implicated upregulated caveolin-1
expression in the tumorigenesis of multiple epithelial tumors [49], how
caveolin-1 regulates Notch1 activation warrants further investigations.
To date, more than 100 γ-secretase inhibitors have been developed
to target Notch signaling, many of which are currently in clinical
trials. The mechanism by which the ILK inhibitor T315 inhibits
γ-secretase enzyme activity is distinct from that of known γ-secretase
inhibitors [50] and thus might have therapeutic value in circumvent-
ing resistance of cancer cells to γ-secretase inhibitors. For example, it
has been reported that loss of phosphatase and tensin homolog
(PTEN) function in T-cell acute lymphoblastic leukemia led to
resistance to γ-secretase inhibitors as a result of constitutive activation
of Akt signaling [51]. In light of the frequent mutation or inactivation
of PTEN in breast cancer [52], the targeting of ILK to suppress IL-6–
driven Notch activation may be a rational therapeutic approach in
patients with breast cancer.
In summary, we obtained in vitro and in vivo evidence that ILK
plays an important role in mediating the IL-6–induced expansion of
the breast CSC population through Notch activation (Figure 6F).
Our data suggest that ILK regulates γ-secretase assembly/stability
through a caveolin-1–dependent mechanism in caveolae. Therefore,
targeting ILK might foster new therapeutic strategies to eliminate the
CSC population in advanced metastatic breast cancer.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.06.001.
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